Navigation Links
Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
Date:12/4/2012

SAN DIEGO, Dec. 4, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will provide details of obesity therapeutics market research including the results of surveys of 1,000 physicians and 6,000 patients during an Analyst Day event on December 18, 2012. The Company will also provide an update to the Contrave® Light Study and discuss U.S. and EU regulatory planning.

The Analyst Day event will be held in New York City on December 18, 2012 from 9 a.m. to 12 p.m. Eastern Time.

While attendance in person is by invitation only, Orexigen will webcast the Analyst Day presentations. The webcast can be accessed live on the Investor Relations section of the Orexigen website at www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.
 

Source:
Orexigen Therapeutics
McDavid Stilwell
Vice President, Corporate Communications & Business Development
858-875-8600


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
2. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
3. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
4. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
7. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
8. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
9. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
10. Flexion Therapeutics Secures $20 Million in Series B Financing
11. Echo Therapeutics Announces Proposed Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  M3 Biotechnology Inc., spurred by a major "team investment" by Bruce Montgomery , ... an oversubscribed Series A-Round, according to CEO Leen Kawas , PhD. ... ... ... Kawas said the ...
(Date:2/11/2016)... Calif. , Feb. 11, 2016  AcelRx Pharmaceuticals, ... podium presentation will be made at the 38th annual ... and Wound Care Symposium, which is being held February ... international conference covers the latest advancements in wound healing, ... the American Burn Association, Australian-New Zealand Burns Association, Academy ...
(Date:2/11/2016)... TEL AVIV, Israel , Feb. 11, 2016  Galmed ... clinical-stage biopharmaceutical company focused on the development of a ... announced today that its Chief Medical Officer, Dr. ... retiring from Galmed as Chief Medical Officer and from ... 2016 due to her reaching retirement age. ...
Breaking Medicine Technology:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... J.R. Garrett Esq. as General Counsel. Garrett will focus on contract negotiations, corporate ... audits, privacy and security law, and best practices in data breaches for the ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein Inc. ... Infusion Therapy Standards of Practice, to include vascular visualization as a standard practice. ... 85% share of the market, facilitates adherence to this standard with its easy ...
(Date:2/11/2016)... ... ... The annual list showcases the 20 Most Promising SharePoint Solution Providers in 2015. ... to the SharePoint ecosystem. A panel of experts and members of CIOReview’s editorial board ... promote technology entrepreneurship. , The survey was made at the end of the ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... dynamometers and ergoFET force gauges used in physical therapy, occupational therapy and sports ... sensor for resistance cord exercise and therapy, introduces its new microFET Digital Pinch ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... coverage results in significantly higher rates of several common cancer screenings, especially among ... in better outcomes and survival rates. , The study,“What Does Medicaid Expansion ...
Breaking Medicine News(10 mins):